CY1106961T1 - Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης - Google Patents

Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης

Info

Publication number
CY1106961T1
CY1106961T1 CY20071101390T CY071101390T CY1106961T1 CY 1106961 T1 CY1106961 T1 CY 1106961T1 CY 20071101390 T CY20071101390 T CY 20071101390T CY 071101390 T CY071101390 T CY 071101390T CY 1106961 T1 CY1106961 T1 CY 1106961T1
Authority
CY
Cyprus
Prior art keywords
risk
reduce
thomboevological
parenergy
homocycine
Prior art date
Application number
CY20071101390T
Other languages
English (en)
Inventor
Gabor Bogye
Original Assignee
Gabor Bogye
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gabor Bogye filed Critical Gabor Bogye
Publication of CY1106961T1 publication Critical patent/CY1106961T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Η παρούσα εφεύρεση αφορά φαρμακευτική σύνθεση (συνθέσεις) που περιλαμβάνουν στεροειδή ορμόνη (ορμόνες) τύπου προγεστερόνης και ένωση (ενώσεις) που μειώνουν το επίπεδο ομοκυστεΐνης στο πλάσμα ανθρώπου, ικανές μείωσης του κινδύνου θρομβοεμβολικών παρενεργειών συνθέσεων τύπου προγεστερόνης. Οι παράγοντες μείωσης της περιεκτικότητας ομοκυστεΐνης πλάσματος μπορεί να επιλέγονται από φολικό οξύ, βιταμίνη Β6, βιταμίνη Β12, βεταΐνη, χολίνη, ακετυλοκυστεΐνη και μεταβολικούς προδρόμους, ανάλογα ή και παράγωγα αυτών. Η εφεύρεση επίσης κατευθύνεται στη χρήση των αναφερθέντων παραγόντων μείωσης στο πλάσμα.
CY20071101390T 1999-02-01 2007-10-29 Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης CY1106961T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900213A HUP9900213A1 (hu) 1999-02-01 1999-02-01 Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
EP00903916A EP1148882B1 (en) 1999-02-01 2000-01-28 Use of a plasma homocysteine content reducing agent for the reduction of the thromboembolic side effect risk induced by gestagen type hormones

Publications (1)

Publication Number Publication Date
CY1106961T1 true CY1106961T1 (el) 2012-09-26

Family

ID=89997698

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101390T CY1106961T1 (el) 1999-02-01 2007-10-29 Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης

Country Status (10)

Country Link
EP (1) EP1148882B1 (el)
AT (1) ATE368464T1 (el)
AU (1) AU2566400A (el)
CY (1) CY1106961T1 (el)
DE (1) DE60035771T2 (el)
DK (1) DK1148882T3 (el)
ES (1) ES2286997T3 (el)
HU (1) HUP9900213A1 (el)
PT (1) PT1148882E (el)
WO (1) WO2000044385A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102005053771A1 (de) 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131292B (en) * 1982-12-01 1987-03-11 Dr Christopher H Mortimer Progestational pharmaceutical formulations
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.

Also Published As

Publication number Publication date
ES2286997T3 (es) 2007-12-16
HUP9900213A1 (hu) 2000-12-28
EP1148882A1 (en) 2001-10-31
DE60035771D1 (de) 2007-09-13
AU2566400A (en) 2000-08-18
DK1148882T3 (da) 2007-11-26
HU9900213D0 (en) 1999-03-29
DE60035771T2 (de) 2008-04-30
EP1148882B1 (en) 2007-08-01
WO2000044385A1 (en) 2000-08-03
ATE368464T1 (de) 2007-08-15
PT1148882E (pt) 2007-11-08

Similar Documents

Publication Publication Date Title
ATE438634T1 (de) Benzothiazepinderivate
DE69804281T2 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Leberkrankheiten
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
BR0312464A (pt) Inibidores de tirosina quinases
RS50360B (sr) Farmaceutske formulacije derivata platine
DE60305724D1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
BRPI0203172B8 (pt) composição farmacêutica para acondroplasia
ATE329586T1 (de) Zusammensetzungen enthaltend carotenoide und deren verwendung zur verhinderung hormon- induzierter nebenwirkungen
ATE454379T1 (de) Benzothiazepin-derivate für die behandlung von hyperlipidemia
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
TW200517106A (en) Sustained release pharmaceutical compositions
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
SI1750703T1 (sl) Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
CY1106961T1 (el) Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
BR0003233A (pt) Pirazol, uso do composto na preparação de um medicamento e composição
HK1090062A1 (en) Colchicoside analogues
PE20020769A1 (es) Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos
ITMI931723A1 (it) Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
SE9902742D0 (sv) New pharmaceutical formultion
ATE417619T1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
AR008764A1 (es) Sales hidratadas de n,n'-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo.
IT1255471B (it) Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
EP1322315A4 (en) FORMULATIONS CONTAINING URSODESOXYCHOLIC ACID FOR REDUCING OR SUPPRESSING TOXICITY OF ENDOCRINE MODULATORS